Sonali Bose1, Christian Bime2, Robert J Henderson3, Kathryn V Blake4, Mario Castro5, Emily DiMango6, Nicola A Hanania7, Janet T Holbrook3, Charles G Irvin8, Monica Kraft2, Stephen P Peters9, Joan Reibman10, Elizabeth A Sugar11, Kaharu Sumino5, Robert A Wise3, Linda Rogers12. 1. Icahn School of Medicine at Mount Sinai, New York, NY; Johns Hopkins School of Medicine, Baltimore, Md. 2. University of Arizona College of Medicine, Tucson, Ariz. 3. Johns Hopkins School of Medicine, Baltimore, Md. 4. Nemours Children's Health System, Jacksonville, Fla. 5. Washington University School of Medicine, St Louis, Mo. 6. Columbia University College of Physicians and Surgeons, New York, NY. 7. Baylor College of Medicine, Houston, Texas. 8. University of Vermont, Burlington, Vt. 9. Wake Forest University School of Medicine, Winston-Salem, NC. 10. New York University School of Medicine, New York, NY. 11. Johns Hopkins Bloomberg School of Public Health, Baltimore, Md. 12. Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: linda.rogers@mssm.edu.
Abstract
BACKGROUND: Biomarkers that can predict loss of asthma control among patients being considered for step-down therapy in well-controlled disease are lacking. OBJECTIVE: To evaluate whether baseline biomarkers of type 2 airway inflammation and/or serial measurement of fractional exhaled nitric oxide (Feno) predict loss of asthma control as therapy is stepped down. METHODS: In subanalyses of a multicenter randomized, double-blind, parallel 3-arm trial comparing strategies for step-down therapy in well-controlled asthma (Long-Acting Beta-Agonist Step-Down Study), we assessed whether baseline atopy as determined by serum aeroallergen allergy screening test (Phadiatop), baseline serum eosinophil peroxidase, or baseline or serial Feno measurements during follow-up predicted the time to loss of asthma control among participants. Loss of asthma control was defined in the study protocol. We analyzed these associations in adjusted models including all participants, after testing for interactions with assignment to each of the 3 treatment groups (continuation of stable dose of combination inhaled corticosteroid-long-acting beta-agonist, step-down of inhaled corticosteroid, or discontinuation of long-acting bronchodilator). RESULTS: Four hundred forty-seven of the 553 Long-Acting Beta-Agonist Step-Down Study participants who were randomized to 1 of 3 treatment arms and had at least 1 biomarker measurement were included in this analysis. At baseline, higher levels of Feno were significantly associated with greater levels of multiallergen IgE levels (P < .001), but not with serum eosinophil peroxidase (P = .742). Among all participants as a group, elevations in baseline biomarkers were not predictive of a higher risk of treatment failure. In addition, Feno levels measured serially at 6-week intervals demonstrated that compared with participants with low levels (<25 parts per billion), those with intermediate (25-50 parts per billion) and high (>50 parts per billion) levels did not have significantly increased likelihood of subsequent treatment failure (hazard ratios, 1.03 [95% CI, 0.59-1.78] and 1.29 [95% CI, 0.65-2.54], respectively). There were no significant interactions of treatment group and baseline biomarkers. CONCLUSIONS: In patients with well-controlled asthma, neither baseline levels of type 2 airway inflammatory biomarkers nor serial measures of Feno are strong predictors of treatment failure.
BACKGROUND: Biomarkers that can predict loss of asthma control among patients being considered for step-down therapy in well-controlled disease are lacking. OBJECTIVE: To evaluate whether baseline biomarkers of type 2 airway inflammation and/or serial measurement of fractional exhaled nitric oxide (Feno) predict loss of asthma control as therapy is stepped down. METHODS: In subanalyses of a multicenter randomized, double-blind, parallel 3-arm trial comparing strategies for step-down therapy in well-controlled asthma (Long-Acting Beta-Agonist Step-Down Study), we assessed whether baseline atopy as determined by serum aeroallergen allergy screening test (Phadiatop), baseline serum eosinophil peroxidase, or baseline or serial Feno measurements during follow-up predicted the time to loss of asthma control among participants. Loss of asthma control was defined in the study protocol. We analyzed these associations in adjusted models including all participants, after testing for interactions with assignment to each of the 3 treatment groups (continuation of stable dose of combination inhaled corticosteroid-long-acting beta-agonist, step-down of inhaled corticosteroid, or discontinuation of long-acting bronchodilator). RESULTS: Four hundred forty-seven of the 553 Long-Acting Beta-Agonist Step-Down Study participants who were randomized to 1 of 3 treatment arms and had at least 1 biomarker measurement were included in this analysis. At baseline, higher levels of Feno were significantly associated with greater levels of multiallergen IgE levels (P < .001), but not with serum eosinophil peroxidase (P = .742). Among all participants as a group, elevations in baseline biomarkers were not predictive of a higher risk of treatment failure. In addition, Feno levels measured serially at 6-week intervals demonstrated that compared with participants with low levels (<25 parts per billion), those with intermediate (25-50 parts per billion) and high (>50 parts per billion) levels did not have significantly increased likelihood of subsequent treatment failure (hazard ratios, 1.03 [95% CI, 0.59-1.78] and 1.29 [95% CI, 0.65-2.54], respectively). There were no significant interactions of treatment group and baseline biomarkers. CONCLUSIONS: In patients with well-controlled asthma, neither baseline levels of type 2 airway inflammatory biomarkers nor serial measures of Feno are strong predictors of treatment failure.
Authors: Heather Powell; Vanessa E Murphy; D Robin Taylor; Michael J Hensley; Kirsten McCaffery; Warwick Giles; Vicki L Clifton; Peter G Gibson Journal: Lancet Date: 2011-09-10 Impact factor: 79.321
Authors: Luis Garcia-Marcos; Manuel Sanchez-Solis; Antonia E Martinez-Torres; Jose M Lucas Moreno; Vicente Hernando Sastre Journal: Pediatr Allergy Immunol Date: 2007-03-07 Impact factor: 6.377
Authors: Vanessa E Murphy; Megan E Jensen; Joerg Mattes; Michael J Hensley; Warwick B Giles; Michael J Peek; Andrew Bisits; Leonie K Callaway; Kirsten McCaffery; Helen L Barrett; Paul B Colditz; Sean K Seeho; John Attia; Andrew Searles; Christopher Doran; Heather Powell; Peter G Gibson Journal: BMC Pregnancy Childbirth Date: 2016-05-17 Impact factor: 3.007